Parotid-sparing IMRT for Nasopharyngeal Cancer

Completed

• Conditions: Nasopharyngeal Cancers; Intensity Modulated Radiotherapy With Chemotherapy

• Registration Number: NCT02149641
• Lead Sponsor: Royal Marsden NHS Foundation Trust

Brief Summary

In the treatment of nasopharyngeal cancers, to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.

Detailed Description

The purpose of this study was to determine the feasibility in delivering induction chemotherapy and concomitant chemotherapy with IMRT in the treatment of locally advanced nasopharyngeal cancers and to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.

Study Timeline

• Study Start: 2006-02
• Primary Completion: 2011-04
• Study Completion: 2012-04
• Status Verified: 2014-05
• Study First Submitted: 2014-05-26
• Study First Submitted QC: 2014-05-26
• Last Update Submitted: 2014-05-26
• Study First Posted: 2014-05-29
• Last Update Posted: 2014-05-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• nasopharyngeal cancers

Exclusion Criteria

• Patients <16 years old or with a previous malignancy other than non-melanomatous skin cancer were excluded

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the incidence of ≥G2 xerostomia at 1 year using the subjective component LENTSOMA	12 months

Secondary Outcome Measures

Name	Time	Method
Acute radiation toxicities	0-3 months
loco-regional disease-free survival (LRDFS), progression-free survival (PFS) and overall survival (OS)	2 years
chemotherapy compliance and toxicities	0-12 weeks
Late radiation toxicities	3-24 months

Trial Locations

Locations (1)

The Royal Marsden NHS Foundation Trust; 🇬🇧 London, United Kingdom